Testosterone levels during systemic and inhaled corticosteroid therapy

Testosterone has importance both as a sex hormone and as an anabolic steroid promoting bone formation. Osteoporosis is associated with both hypogonadism and corticosteroid therapy. Testosterone levels are reduced by long term prednisolone treatment. Although high dose inhaled corticosteroid therapy may cause a variety of systemic effects including adrenal suppression, dermal thinning and a reduction in total bone calcium, its effect on testosterone levels is not known. Testosterone, luteinizing hormone, follicle stimulating hormone and sex hormone binding globulin were therefore measured in 35 male patients with respiratory disease attending an outpatient clinic (median age 58, range 21–75 years). They were grouped according to steroid therapy and compared with 19 age matched controls. Mean ( sd) testosterone levels were 33% lower in 12 men on long term oral prednisolone [14·5 (6·0) nmol l −1] than in controls [21·7 (6·3) nmol l −1], but were not significantly reduced in 10 patients on low dose inhaled beclomethasone [200–800 μg day −1: 19·7 (3·7)] nor in 13 men taking high dose inhaled beclomethasone [1500–2250 μg day −1: 17·9 (5·6)]. Levels of luteinizing hormone, follicle stimulating hormone and sex hormone binding globulin were similar in all four groups. These cross sectional data confirm that long term systemic corticosteroid therapy reduces testosterone levels. However, testosterone was reduced by only 18% ( ns) by long term inhaled corticosteroids. Other mechanisms to explain the disordered bone metabolism should now be explored.